We Need a MERS Vaccine, but High Costs, Regulations Make One Unlikely

New technologies give vaccine developers a boost in early development, but large-scale testing and production are bogged down by high costs and lengthy trials.

Middle East respiratory syndrome, or MERS, is spreading across the globe, and while a vaccine could be developed, theres little commercial incentive to make one.